CY2503B1 - Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate. - Google Patents

Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.

Info

Publication number
CY2503B1
CY2503B1 CY0500016A CY0500016A CY2503B1 CY 2503 B1 CY2503 B1 CY 2503B1 CY 0500016 A CY0500016 A CY 0500016A CY 0500016 A CY0500016 A CY 0500016A CY 2503 B1 CY2503 B1 CY 2503B1
Authority
CY
Cyprus
Prior art keywords
fluoxetine
transdermal administration
acetate
composition
maleate
Prior art date
Application number
CY0500016A
Other languages
English (en)
Inventor
Robert M Gale
Melinda K Nelson
Michel J N Cormier
Suneel K Gupta
Patricia S Campbell
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CY2503B1 publication Critical patent/CY2503B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY0500016A 1996-07-15 2005-03-04 Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate. CY2503B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2172796P 1996-07-15 1996-07-15

Publications (1)

Publication Number Publication Date
CY2503B1 true CY2503B1 (en) 2005-09-02

Family

ID=32848735

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500016A CY2503B1 (en) 1996-07-15 2005-03-04 Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.

Country Status (8)

Country Link
EP (1) EP0946184B1 (xx)
AT (2) ATE322272T1 (xx)
AU (1) AU3601897A (xx)
CY (1) CY2503B1 (xx)
DE (2) DE69735656T2 (xx)
ES (2) ES2259746T3 (xx)
HK (1) HK1063148A1 (xx)
WO (1) WO1998002169A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
PT1666026E (pt) † 1999-02-08 2012-03-15 Intarcia Therapeutics Inc Veículos viscosos não aquosos biocompatíveis monofásicos e métodos para a preparação dos mesmos
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
CA2509526A1 (en) * 2002-09-24 2004-04-15 Combinatorx, Incorporated Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2007117581A2 (en) * 2006-04-06 2007-10-18 Collegium Pharmaceutical, Inc. Stabilized transdermal bupropion preparations
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411738A (en) * 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
AU657973B2 (en) * 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
AU6410494A (en) * 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
WO1997010816A1 (en) * 1995-09-22 1997-03-27 Eli Lilly And Company METHODS OF TREATING β-AMYLOID-ASSOCIATED CONDITIONS

Also Published As

Publication number Publication date
EP0946184B1 (en) 2004-09-29
ES2227707T3 (es) 2005-04-01
DE69735656T2 (de) 2006-08-24
DE69735656D1 (de) 2006-05-18
ES2259746T3 (es) 2006-10-16
DE69730988D1 (de) 2004-11-04
WO1998002169A2 (en) 1998-01-22
ATE277620T1 (de) 2004-10-15
AU3601897A (en) 1998-02-09
HK1063148A1 (en) 2004-12-17
EP0946184A2 (en) 1999-10-06
DE69730988T2 (de) 2006-02-23
WO1998002169A3 (en) 1998-03-12
ATE322272T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
US4746515A (en) Skin permeation enhancer compositions using glycerol monolaurate
US5686097A (en) Monoglyceride/lactate ester permeation enhancer for codelivery of steroids
US4568343A (en) Skin permeation enhancer compositions
MX9709162A (es) Composiciones mejoradas de la permeacion en la piel que usan lactilatos de acilo.
US5000956A (en) Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
WO1998017315A3 (en) Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CA2132865A1 (en) Transdermal administration of oxybutynin
TW366286B (en) Flavour-masked pharmaceutical compositions
KR900701274A (ko) 남용 가능성을 감소시킨 용량 제형
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
GR3032523T3 (en) Therapeutic preparation for the transdermal administration of active substances
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
DE69521688D1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
AU2313297A (en) Transdermally administered dextromethorphan as antitussive agent
US5077054A (en) Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
JPH0640947A (ja) 経皮吸収製剤用組成物および経皮吸収製剤
CA2333076A1 (en) Topical application of muscarinic analgesic drugs such as neostigmine
AU5105699A (en) Formulations for the transdermal administration of fenoldopam
ES2184561A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
AU7576000A (en) Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines
CA2235617A1 (en) Therapeutic preparation for the transdermal administration of active substances